Related Experiment Video
Updated: Jun 14, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Clinical, Laboratory, Molecular, and Reproductive Aspects of Combined Deficiency of Factors V and VIII
1Clinical and Diagnostic Department of Hematology and Hemostasis Disorders, National Medical Research Center for Hematology, Moscow, Russia.
Insights
Congenital combined deficiency of factor V and factor VIII (F5F8D) is a rare genetic bleeding disorder caused by mutations in LMAN1 or MCFD2, affecting FV and FVIII transport. Diagnosis and management are complicated by the simultaneous decrease of both factors.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Congenital combined deficiency of factor V (FV) and factor VIII (FVIII), known as F5F8D, is a rare hereditary coagulopathy.
- It affects approximately 1:1,000,000 individuals globally, with higher prevalence in regions with consanguineous marriages.
Purpose of the Study:
- To review recent advancements in the clinical, laboratory, and molecular understanding of F5F8D.
- To highlight diagnostic and management challenges, particularly for female patients.
Main Methods:
- Review of existing literature on F5F8D.
- Analysis of genetic mutations in LMAN1 and MCFD2.
- Summary of clinical manifestations and laboratory findings.
Main Results:
- F5F8D results from mutations in LMAN1 or MCFD2, impacting the ER-to-Golgi transport of FV and FVIII.
- Patients exhibit reduced plasma levels of both FV and FVIII (typically 5-30% of normal).
- Clinical presentation is usually a mild to moderate hemorrhagic syndrome.
Conclusions:
- F5F8D presents unique diagnostic and management challenges due to the combined deficiency of FV and FVIII.
- Special considerations are necessary for family planning, pregnancy, and parturition in affected females.
- Further research is needed to optimize treatment strategies and patient care.
Abstract:
Congenital combined deficiency of factor V (FV) and factor VIII (FVIII; F5F8D, OMIM 227300) is a rare hereditary coagulopathy and accounts for approximately 3% of cases of rare coagulation disorders. The prevalence of this disease in the general population is estimated to be 1:1,000,000 and is significantly higher in regions where consanguineous marriages are permitted, such as the Mideast and South Asia. The disease has an autosomal recessive mode of inheritance and therefore occurs with an equal incidence among males and females. Heterozygous mutation carriers usually do not have clinical manifestations. The molecular basis of this disease differs from that of stand-alone congenital deficiencies of FVIII and FV. F5F8D is caused by mutations in either LMAN1 or MCFD2, which encode components of a cargo receptor complex for endoplasmic reticulum to Golgi transport of FV and FVIII, leading to defects in an intracellular transport pathway shared by these two coagulation factors. Congenital combined deficiency of FV and FVIII is characterized by decreased activities of both FV and FVIII in plasma, usually to 5 to 30% of normal. Clinical manifestations in most cases are represented by mild or moderate hemorrhagic syndrome. The simultaneous decreases of two coagulation factors present complications in the diagnosis and management of the disease. In female patients, the disease requires a special approach for family planning, pregnancy management, and parturition. This review summarizes recent progress in clinical, laboratory, and molecular understanding of this disorder.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Vitamins
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

